Previously, AIM1L mRNA overexpression was identified in several cancer cell lines including prostate cancer, bladder inverted papilloma, bladder cancer, colon cancer, pancreas cancer, ovarian cancer, endometrial cancer, and breast cancer. Here, CRYBG2 is linked to prostate cancer.